Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-05-14T03:18:24.960Z Has data issue: false hasContentIssue false
  • English
  • Français

Prognostic Indicators in an Aggressive Pituitary Crooke's Cell Adenoma

Published online by Cambridge University Press:  02 December 2014

K. Kovacs ,
C.C. Diep ,
E. Horvath ,
M. Cusimano ,
H. Smyth ,
C. Coire ,
M. Lombardero ,
B.W. Scheithauer  and
R.V. Lloyd
K. Kovacs
Affiliation:
Department of Laboratory Medicine and Pathobiology, St. Michaels Hospital, University of Toronto, Toronto, ON, Canada
C.C. Diep
Affiliation:
Department of Laboratory Medicine and Pathobiology, St. Michaels Hospital, University of Toronto, Toronto, ON, Canada
E. Horvath
Affiliation:
Department of Laboratory Medicine and Pathobiology, St. Michaels Hospital, University of Toronto, Toronto, ON, Canada
M. Cusimano
Affiliation:
Department of Neurosurgery, St. Michaels Hospital, University of Toronto, Toronto, ON, Canada
H. Smyth
Affiliation:
Department of Neurosurgery, St. Michaels Hospital, University of Toronto, Toronto, ON, Canada
C. Coire
Affiliation:
Department of Pathology, Trillium Health Centre, Mississauga, ON, Canada
M. Lombardero
Affiliation:
Department of Anatomy, University of Santiago de Compostela, Lugo, Spain
B.W. Scheithauer*
Affiliation:
Department of Pathology, Mayo Clinic, Rochester, MN, USA
R.V. Lloyd
Affiliation:
Department of Pathology, Mayo Clinic, Rochester, MN, USA
*
Mayo Clinic, 200 First Street, SW, Rochester, MN 55905 USA
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

To investigate prognostic indicators in an aggressive Crooke's cell adenoma of the pituitary.

Methods:

The surgically removed tumor was studied by histology, immunohistochemistry and transmission electron microscopy.

Results:

An aggressive invasive sellar tumor removed by repeated surgeries from a 43-year-old woman with pituitary related Cushing's disease was classified as a Crooke's cell adenoma of the pituitary. The application of several cell proliferation markers confirmed the aggressive nature of the tumor.

Conclusions:

The investigation of the present case provides additional evidence that pituitary Crooke's cell adenomas may possess aggressive behavior.

Résumé:

RÉSUMÉ:Objectif:

Investiguer les indicateurs du pronostic de l’adénome pituitaire à cellules de Crooke.

Méthodes:

Le spécimen tumoral chirurgical a été étudié par histologie, immunohistochimie et microscopie électronique.

Résultats:

Une tumeur envahissante de la selle turcique a été enlevée chirurgicalement à plusieurs reprises chez une femme âgée de 43 ans ayant un Cushing d’origine pituitaire. Cette tumeur a été classifiée comme étant un adénome pituitaire à cellules de Crooke. L’étude au moyen de plusieurs marqueurs de prolifération cellulaire a confirmé la nature agressive de la tumeur.

Conclusions:

L’étude de ce cas démontre que les adénomes pituitaires à cellules de Crooke peuvent être envahissants.

Type
Case Report
Information
Canadian Journal of Neurological Sciences , Volume 32 , Issue 4 , November 2005 , pp. 540 - 545
Copyright
Copyright © The Canadian Journal of Neurological 2005

References

1. Wagermark, J, Wersall, J. Ultrastructural features of Crooke’s changes in pituitary basophil cells. Acta Pathol Microbiol Scand 1968; 72: 367–375.CrossRefGoogle ScholarPubMed
2. Halmi, NS, McCormick, WF, Decker, DA Jr. The natural history of hyalinization of ACTH-MSH cells in man. Arch Path 1971; 91: 318–326.Google Scholar
3. DeCicco, FA, Dekker, A, Yunis, EJ. Fine structure of the Crooke’s hyaline change in the human pituitary gland. Arch Pathol 1972; 94: 65–70.Google Scholar
4. Felix, IA, Horvath, E, Kovacs, K. Massive Crooke’s hyalinization in corticotroph cell adeomas of the human pituitary. A histological, immunocytological, and electron microscopic study of three cases. Acta Neurochir 1981; 58: 235–243.CrossRefGoogle ScholarPubMed
5. Horvath, E, Kovacs, K, Josse, R. Pituitary corticotroph cell adenoma with marked abundance of microfilaments. Ultrastruct Pathol 1983; 5: 249–255.Google Scholar
6. Neumann, PE, Horoupian, DS, Goldman, JE, Hess, MA. Cytoplasmic filaments of Crooke’s hyaline change belong to the cytokeratin class. An immunocytochemical and ultrastructural study. Am J Pathol 1984; 116: 214–222.Google Scholar
7. Kovacs, K. The pathology of Cushing’s disease. J Steroid Biochem Mol Biol 1993; 45: 179–182.Google Scholar
8. Kovacs, K, Horvath, E, Stefaneanu, L, et al. Two cases of pituitary Crooke’s cell adenoma without Cushing’s disease: a histologic, immunocytochemical, electron microscopic and in situ hybridization study. Endocr Pathol 1999; 10: 65–72.Google Scholar
9. George, DH, Scheithauer, BW, Kovacs, K, et al. Crooke’s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 2003; 27: 1330–1336.Google Scholar
10. Kovacs, K, Stefaneanu, L, Horvath, et al. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. J Neurosurg 1995; 82: 886–890.Google Scholar
11. Kovacs, K, Giannini, C, Scheithauer, BW, et al. Pituitary changes in Ataxia-telangiectasia syndrome: an immunocytochemical, in situ hybridization, and DNA cytometric study of three cases. Endocr Pathol 1997; 8: 195–203.Google Scholar
12. Jugenburg, M, Kovacs, K, Stefaneanu, L, Scheithauer, BW. Vasculature in non-tumorous hypophyses, pituitary adenomas, and carcinomas: a quantitative morphologic study. Endocr Pathol 1995; 6: 115–124.Google Scholar
13. Vidal, S, Scheithauer, BW, Kovacs, K. Vascularity in nontumorous human pituitaries and incidental microadenomas: a morphometric study. Endocr Pathol. 2000; 11: 215–227.CrossRefGoogle ScholarPubMed
14. Vidal, S, Kovacs, K, Horvath, E, et al. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 2001; 438: 595–602.Google Scholar
15. Thapar, K, Yamada, Y, Scheithauer, BW, et al. Assessment of mitotic activity in pituitary adenomas and carcinomas. Endocr Pathol 1996; 7: 215–221.CrossRefGoogle ScholarPubMed
16. Vidal, S, Kovacs, K, Bell, D, et al. Cyclooxygenase-2 expression in human pituitary tumors. Cancer 2003; 97: 2814–2821.CrossRefGoogle ScholarPubMed
17. Crooke, AC. A change in the basophil cells of the pituitary gland common to conditions which exhibit the syndrome attributed to basophil adenoma. J Pathol Bacteriol 1935; 41: 339–349 Google Scholar
18. Horvath, E, Scheithauer, BW, Kovacs, K, Lloyd, RV. Hypothalamus and pituitary. In: Graham, DI, Lantos, PL (Eds). Greenfield’s Neuropathology Vol 1, (7th Ed), New York Arnold Publi, NY; 2002: 983–1062.Google Scholar
19. Ikeda, H, Yoshimoto, T, Ogawa, Y, Mizoi, K, Murakami, O. Clinicopathological study of Cushing’s disease with large pituitary adenoma. Clin Endocrinol 1997; 46:669–679.Google Scholar
20. Thapar, K, Kovacs, K, Scheithauer, BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996; 38: 99106.Google Scholar
21. Kovacs, K, Scheithauer, BW, Horvath, E, Lloyd, RV. The World Health Organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 1996; 78: 502510.Google Scholar
22. Thapar, K, Scheithauer, BW, Kovacs, K, Pernicone, PJ, Laws, ER Jr. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 1996; 38: 765–770.Google Scholar
23. Jin, L, Qian, X, Kulig, E, et al. Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 1997; 151: 509–519.Google Scholar
24. Lidhar, R, Korbonits, M, Jordan, S, et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 1999; 84:3823- 3830.Google Scholar
25. Vidal, S, Kovacs, K, Horvath, E et al. Topoisomerase II alpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol 2002; 15: 1205–1212.CrossRefGoogle ScholarPubMed
26. Riss, D, Jin, L, Qian, X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003; 63: 2251–2255.Google Scholar
27. Lloyd, RV, Scheithauer, BW, Kuroki, T, et al. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 1999; 10:229–235.CrossRefGoogle ScholarPubMed
28. Vidal, S, Kovacs, K, Cohen, SM et al. Localization of vascular endothelial growth factor in nontumorous human pituitaries. Endocr Pathol 1999; 10: 109–122.Google Scholar
29. Yamamoto, T, Nishizawa, Y, Tsuji, M, et al. Expression of vascular endothelial growth factor in normal pituitary cells and pituitary adenomas producing adrenocorticotropic hormone. Endocr Pathol 1999; 10:157–164.Google Scholar
30. de la Torre, NG, Wass, JA, Turner, HE. Morphologic changes and molecular regulation of angiogenesis in pituitary adenomas. Front Horm Res 2004; 32: 133–145.Google Scholar
31. Kovacs, K, Rotondo, F, Stefaneanu, L, et al. Glucocorticoid receptor expression in nontumorous human pituitaries and pituitary adenomas. Endocr Pathol 2000; 11: 267–276.Google Scholar
32. Gaffey, TA, Scheithauer, BW, Lloyd, RV, et al. Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg 2002; 96: 352–360.Google Scholar